2nd Non-Viral RNA Delivery Systems Summit

As the first and only industry-led forum dedicated to tackling the most pressing challenges when delivering RNA-based drugs, the 2nd Annual Non-Viral RNA Delivery Systems Summit is set to unite 50+ key thought leaders in biopharma and academia eager to help RNA vaccines and therapeutics reach their medical potential.

Hear from 18+ expert speakers across 3 days of data-driven presentations, technical workshops, and panel discussions to accelerate formulation, promote cell specificity, manipulate immunogenicity, whilst uncovering the latest delivery vehicles revolutionizing targeted RNA delivery.

URLs:
Website: https://go.evvnt.com/1837142-0?pid=2874
Brochure: https://go.evvnt.com/1837142-3?pid=2874

Category: Conferences | Science, Health and Medicine

Prices:
Drug Developer - Conference + 2 Workshops: USD 4297.00,
Drug Developer - Conference + 1 Workshop: USD 3648.00,
Drug Developer - Conference Only: USD 2999.00,
Academic Pricing - Conference + 2 Workshops: USD 3697.00,
Academic Pricing - Conference + 1 Workshop: USD 3148.00,
Academic Pricing - Conference Only: USD 2599.00,
Solution Provider Pricing - Conference + 2 Workshops: USD 5297.00,
Solution Provider Pricing - Conference + 1 Workshop: USD 4548.00,
Solution Provider Pricing - Conference Only: USD 3799.00

Speakers: Andy Geall, Co-Founder and Chief Development Officer, Replicate Bioscience, Chad Miller, Head of Research, Nosis Biosciences, De-Min Zhu, Chief Executive Officer and President, Cureport, Gemma Navarro, Associate Director, Curevac GmbH, Gregory Fiore, Chief Executive Officer, Exacis Biotherapeutics, Jaap Rip, Chief Scientific Officer, 20Med Therapeutics, Jasdave Chahal, Co-Founder and Chief Scientist, Tiba Biotech LLC, Jay Kim, CEO, K2B Therapeutics Inc., Jeff Atkinson, Executive Director- Process Development and Analytical Sciences, Omega Therapeutics, Jessica Rouge, Associate Professor, University of Connecticut, Laura Rotolo, Formulation Chemist, Emory University, Liping Zhou, Senior Director - Advanced Drug Delivery, AstraZeneca, Mano Manoharan, Senior Vice President, Alnylam Pharmaceuticals, Manuel Sanchez-Felix, Associate Director, Novartis AG, Merle Fuchs, CEO, Co-Founder, PRAMOMOLECULAR GmbH, Sean Lu, Director of Oligonucleotide Chemistry, Eli Lilly and Co., Sujit Jain, Director - External Manufacturing, SalioGen Therapeutics, Susan Rosenbaum, Founder, Chairman and Chief Executive Officer, Lauren Sciences LLC, Zdravka Medarova, CTO, TransCode Therapeutics Inc.